SCHEMBL1360732

SCHEMBL1360732

CN1CCN(C(=O)c2cc(F)ccc2Cc2cnc(-c3nc4sc(CN5CCOCC5)cn4c(=O)c3O)s2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HRH3 Q9Y5N1 2/20 0.35
MLNR O43193 1/20 0.35
PARP1 P09874 3/20 0.34
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
KCNK3 O14649 4/20 0.33
KCNK9 Q9NPC2 4/20 0.33
WDR5 P61964 1/20 0.33
EPHX2 P34913 1/20 0.33
CNR2 P34972 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1360873 0.96 MLNR (0.38) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12138836 0.90 SMN1; SMN2 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1359078 0.89 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12138821 0.87 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12138948 0.87 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1360560 0.86 GPR6 (0.33) ALDH1A1SMN1; SMN2NPC1RAB9AMLNR
SCHEMBL12138811 0.85 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1360623 0.85 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12880536 0.84 KMT2A (0.38) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12138819 0.84 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US claimed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP claimed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US claimed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP disclosed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
WO-2010000030-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF TPMT, CYP2C19, CYP3A5 ALDH1A1 124/4885SMN1; SMN2 1592/4885MEN1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.